Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

Area of Science:

• Pharmacology
• Neuroscience

Background:

• Parkinson's disease (PD) management often involves levodopa therapy.
• Levodopa's efficacy can be limited by its metabolism.
• Catechol-O-methyltransferase (COMT) plays a role in levodopa breakdown.

Purpose of the Study:

• To evaluate the tolerability, pharmacokinetics, and pharmacodynamics of tolcapone in elderly individuals.
• To assess the effects of tolcapone when coadministered with carbidopa and levodopa.
• To determine optimal dosing for tolcapone as an adjunct therapy.

Main Methods:

• A double-blind, placebo-controlled, ascending multiple-dose study.
• Thirty-six healthy elderly volunteers (55-75 years) received tolcapone (100-800 mg t.i.d.) or placebo with carbidopa/levodopa for 7 days.
• Assessments included tolerability, pharmacokinetics of tolcapone, levodopa, 3-O-methyldopa, and COMT inhibition.

Main Results:

• Tolcapone significantly reduced levodopa metabolism to 3-O-methyldopa, doubling levodopa exposure and half-life without altering peak concentrations.
• COMT inhibition was rapid and sustained, with no observed tolerance.
• Optimal pharmacokinetic effects were achieved with 100 or 200 mg tolcapone t.i.d.; higher doses showed accumulation and increased side effects (nausea, vomiting), particularly in women.

Conclusions:

• Tolcapone is a promising adjunct to levodopa for Parkinson's disease treatment.
• Clinical pharmacology supports a therapeutic regimen of 100 or 200 mg tolcapone t.i.d.
• The combination was generally well-tolerated, with dose-dependent adverse events.